FDA OK's Onyx for brain vascular disorder
This article was originally published in Clinica
The FDA has approved for sale in the US Micro Therapeutics' Onyx liquid embolic system for the treatment of arteriovenous malformations (AVMs), a vascular disorder in the brain. The Irvine, California firm will run a controlled introduction of Onyx in the US through its direct sales force.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.